StockNews.com Initiates Coverage on Oragenics (NYSE:OGEN)

StockNews.com began coverage on shares of Oragenics (NYSE:OGEN) in a research report released on Thursday. The firm issued a sell rating on the stock.

Oragenics Trading Down 3.9 %

Oragenics stock opened at $0.29 on Thursday. The company has a market capitalization of $3.57 million, a PE ratio of -0.04 and a beta of 0.49. Oragenics has a 12 month low of $0.25 and a 12 month high of $7.74. The stock has a 50-day moving average price of $0.35 and a two-hundred day moving average price of $0.97.

Hedge Funds Weigh In On Oragenics

An institutional investor recently bought a new position in Oragenics stock. Virtu Financial LLC bought a new stake in Oragenics, Inc. (NYSE:OGEN) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned about 0.51% of Oragenics at the end of the most recent quarter. Hedge funds and other institutional investors own 18.71% of the company’s stock.

Oragenics Company Profile

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.